34.17

2.74% 0.91

Pharvaris Nv (PHVS)

Overview News Price History Discussions Forecast

Pharvaris Nv stock is traded at $34.17, with a volume of 255.61K. It is up +2.74% in the last 24 hours and up +2.64% over the past month. Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Previous Close:

$33.26

Open:

$33.59

24h Volume:

255.61K

Relative Volume:

0.60

Market Cap:

$2.39B

Revenue:

Net Income/Loss:

$-195.21M

P/E Ratio:

-10.76

EPS:

-3.1763

Net Cash Flow:

$-176.19M

1W Performance:

-2.20%

1M Performance:

+2.64%

6M Performance:

+22.12%

1Y Performance:

+70.42%

1-Day Range:

$33.33

$34.38

1-Week Range:

$33.01

$35.54

52-Week Range:

$19.12

$36.60

Pharvaris Nv Stock (PHVS) Company Profile

Name

Pharvaris Nv

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

Address

Employee

129

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

PHVS's Discussions on Twitter

Compare PHVS vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHVS Pharvaris Nv	34.17	2.39B	0	-195.21M	-176.19M	-3.1763
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Wolfe Research	Outperform
Mar-09-26	Initiated	RBC Capital Mkts	Outperform
Oct-15-25	Initiated	H.C. Wainwright	Buy
Oct-09-25	Upgrade	BofA Securities	Underperform → Neutral
Jun-11-25	Initiated	Guggenheim	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Sep-25-23	Initiated	Wedbush	Outperform
Aug-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-05-22	Initiated	Bryan Garnier	Buy
Sep-13-22	Resumed	JMP Securities	Mkt Outperform
Aug-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-22-22	Downgrade	BofA Securities	Neutral → Underperform
May-25-22	Initiated	JMP Securities	Mkt Outperform
Mar-02-21	Initiated	BofA Securities	Neutral
Mar-02-21	Initiated	Morgan Stanley	Overweight
Mar-02-21	Initiated	Oppenheimer	Outperform
Mar-02-21	Initiated	SVB Leerink	Outperform

View All

Pharvaris Nv Stock (PHVS) Latest News

Jul 24, 2026

Pharvaris N.V. Revenue Breakdown – NASDAQ:PHVS - TradingView

Jul 24, 2026

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? - The Motley Fool

Jul 24, 2026

Jul 22, 2026

Pharvaris publishes review on bradykinin B2 receptor research - Investing.com

Jul 22, 2026

Pharvaris publishes review on bradykinin B2 receptor research By Investing.com - Investing.com Canada

Jul 22, 2026

Jul 20, 2026

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy - Yahoo Finance

Jul 15, 2026

PHVS Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus

Jul 15, 2026

Wells Fargo initiates Pharvaris stock with Overweight rating - Investing.com

Jul 15, 2026

Wells Fargo initiates Pharvaris stock with Overweight rating By Investing.com - Investing.com Canada

Jul 15, 2026